Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells

被引:1
|
作者
Abdelsalam, Mohamed [1 ,2 ]
Zmyslia, Mariia [3 ]
Schmidtkunz, Karin [4 ]
Vecchio, Anita [1 ]
Hilscher, Sebastian [5 ]
Ibrahim, Hany S. [1 ,6 ]
Schutkowski, Mike [5 ]
Jung, Manfred [4 ,7 ]
Jessen-Trefzer, Claudia [3 ,8 ]
Sippl, Wolfgang [1 ,9 ]
机构
[1] Martin Luther Univ Halle Wittenberg, Dept Med Chem, Halle, Germany
[2] Alexandria Univ, Fac Pharm, Dept Pharmaceut Chem, Alexandria, Egypt
[3] Univ Freiburg, Inst Organ Chem, Freiburg, Germany
[4] Univ Freiburg, Inst Pharmaceut Sci, Freiburg, Germany
[5] Martin Luther Univ Halle Wittenberg, Inst Biochem, Dept Enzymol, Halle, Germany
[6] Egyptian Russian Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo, Egypt
[7] Univ Freiburg, CIBSS Ctr Integrat Biol Signalling Studies, Freiburg, Germany
[8] Univ Freiburg, Inst Organ Chem, D-79104 Freiburg, Germany
[9] Martin Luther Univ Halle Wittenberg, Inst Pharm, Dept Med Chem, D-06120 Halle, Germany
关键词
epigenetics; HDACs; hypoxia; nitroreductases; prodrugs; NITROREDUCTASE; HYPOXIA; ENZYME; GDEPT;
D O I
10.1002/ardp.202300536
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although histone deacetylase (HDAC) inhibitors show promise in treating various types of hematologic malignancies, they have some limitations, including poor pharmacokinetics and off-target side effects. Prodrug design has shown promise as an approach to improve pharmacokinetic properties and to improve target tissue specificity. In this work, several bioreductive prodrugs for class I HDACs were designed based on known selective HDAC inhibitors. The zinc-binding group of the HDAC inhibitors was masked with various nitroarylmethyl residues to make them substrates of nitroreductase (NTR). The developed prodrugs showed weak HDAC inhibitory activity compared to their parent inhibitors. The prodrugs were tested against wild-type and NTR-transfected THP1 cells. Cellular assays showed that both 2-nitroimidazole-based prodrugs 5 and 6 were best activated by the NTR and exhibited potent activity against NTR-THP1 cells. Compound 6 showed the highest cellular activity (GI50 = 77 nM) and exhibited moderate selectivity. Moreover, activation of prodrug 6 by NTR was confirmed by liquid chromatography-mass spectrometry analysis, which showed the release of the parent inhibitor after incubation with Escherichia coli NTR. Thus, compound 6 can be considered a novel prodrug selective for class I HDACs, which could be used as a good starting point for increasing selectivity and for further optimization. A new series of prodrugs for class I histone deacetylases (HDACs) was designed and synthesized by masking the zinc-binding group of reported HDAC1-3 inhibitors with different nitroaromatic moieties. Among these prodrugs, compound 6 showed the most potent inhibitory activity against nitroreductase (NTR)-transfected leukemic cells. Liquid chromatography-mass spectrometry analysis confirmed the activation of compound 6 and showed the release of its parent inhibitor after incubation with NTR.image
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors
    Zhao, Le
    Dunne, Christine E.
    Clausen, Dane J.
    Roberts, Justin M.
    Paulk, Joshiawa
    Liu, Haining
    Wiest, Olaf G.
    Bradner, James E.
    Williams, Robert M.
    ISRAEL JOURNAL OF CHEMISTRY, 2017, 57 (3-4) : 319 - 330
  • [32] Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease
    Buerli, Roland W.
    Luckhurst, Christopher A.
    Aziz, Omar
    Matthews, Kim L.
    Yates, Dawn
    Lyons, Kathy. A.
    Beconi, Maria
    McAllister, George
    Breccia, Perla
    Stott, Andrew J.
    Penrose, Stephen D.
    Wall, Michael
    Lamers, Marieke
    Leonard, Philip
    Mueller, Ilka
    Richardson, Christine M.
    Jarvis, Rebecca
    Stones, Liz
    Hughes, Samantha
    Wishart, Grant
    Haughan, Alan F.
    O'Connell, Catherine
    Mead, Tania
    McNeil, Hannah
    Vann, Julie
    Mangette, John
    Maillard, Michel
    Beaumont, Vahri
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (24) : 9934 - 9954
  • [33] RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors
    Khateb, Ali
    Deshpande, Anagha
    Feng, Yongmei
    Lazar, Ikrame
    Lee, Joo Sang
    Fabre, Bertrand
    Li, Yan
    Finlay, Darren
    Fujita, Yu
    Zhang, Tongwu
    Pass, Ian
    Livneh, Ido
    Burian, Carol
    Mason, James R.
    Almog, Ronit
    Horesh, Nurit
    Ofran, Yishai
    Brown, Kevin
    Vuori, Kristiina
    Jackson, Michael
    Ruppin, Eytan
    Deshpande, Aniruddha J.
    Ronai, Ze'ev A.
    BLOOD, 2020, 136
  • [34] Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors
    Mohamed, Mamdouh F. A.
    Shaykoon, Montaser Sh. A.
    Abdelrahman, Mostafa H.
    Elsadek, Bakheet E. M.
    Aboraia, Ahmed S.
    Abuo-Rahma, Gamal El-Din A. A.
    BIOORGANIC CHEMISTRY, 2017, 72 : 32 - 41
  • [35] Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors
    You, Tao
    Chen, Ke
    Wang, Fei-Hai
    Li, Pi-Hong
    Li, Li-Yi
    Wu, Zhi-Hao
    Ni, Kong-Hai
    Zheng, Zhi-Qiang
    CHINESE CHEMICAL LETTERS, 2014, 25 (03) : 474 - 478
  • [36] Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β-elemene scaffold
    Gao, Yuan
    Duan, Jilong
    Dang, Xiawen
    Yuan, Yinghui
    Wang, Yu
    He, Xingrui
    Bai, Renren
    Ye, Xiang-Yang
    Xie, Tian
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
  • [37] Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents
    Guandalini, L.
    Cellai, C.
    Laurenzana, A.
    Scapecchi, S.
    Paoletti, F.
    Romanelli, M. N.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (18) : 5071 - 5074
  • [38] Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors
    Jiang, Bei-Er
    Hu, Jiaxin
    Liu, Hao
    Liu, Zhitao
    Wen, Yu
    Liu, Mingyao
    Zhang, Han-Kun
    Pang, Xiufeng
    Yu, Li-Fang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227
  • [39] Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors
    Abdelkarim, Hazem
    Neelarapu, Raghupathi
    Madriaga, Antonett
    Vaidya, Aditya S.
    Kastrati, Irida
    Karumudi, Bhargava
    Wang, Yue-ting
    Taha, Taha Y.
    Thatcher, Gregory R. J.
    Frasor, Jonna
    Petukhov, Pavel A.
    CHEMMEDCHEM, 2017, 12 (24) : 2030 - 2043
  • [40] Design, synthesis, and biological evaluation of novel nicotinamide derivatives as potential histone deacetylase-3 inhibitors
    Hamoud, Mohamed M. S.
    Pulya, Sravani
    Osman, Nermine A.
    Bobde, Yamini
    Hassan, Abdalla E. A.
    Abdel-Fattah, Hanan A.
    Ghosh, Balaram
    Ghanim, Amany M.
    NEW JOURNAL OF CHEMISTRY, 2020, 44 (23) : 9671 - 9683